WellManaged – Clinical Programs make all the difference.

Clinical pharmacy expertise is at the core of all WellDyneRx solutions. We offer an industry-leading array of clinical programs called WellManaged that perfectly balance optimal clinical outcomes with minimized plan costs. From offerings that effectively treat diabetes and hepatitis C, to programs that reduce the risks associated with high dose opioid use, the WellManaged suite of clinical solutions are evidence-based and promote high quality care.

WellManaged – Diabetes is a comprehensive diabetes management program that:

  • Increases medication adherence rates through patient education
  • Reduces plan spend through aggressive formulary management and waste prevention
  • Improves outcomes through monitoring of key measures

Program participants gain access to dedicated diabetes pharmacists and Certified Diabetes Educators (CDEs) from our specialty division, US Specialty Care (USSC). Our team fosters care coordination by reaching out to providers to alert them about medication non-adherence and to ensure each patient is receiving the most cost-effective and clinically appropriate treatment.

WellManaged – Hepatitis C allows plan sponsors to treat more patients at a lower cost. After a thorough evaluation of all available treatment options and a comprehensive review of evidence-based guidelines, our clinicians recognized the cost-saving potential of agents based on genotype. As a result, WellDyneRx was the first pharmacy benefit manager in the country to adopt a hepatitis C indication-based formulary using Zepatier. Implementing an indication-based HCV formulary in 2017 resulted in a 36% significant increase in the percentage of hepatitis C patients treated with an average cost reduction of 35% per patient.

WellManaged – Opioids employs a multifaceted approach to reduce long-term opioid utilizers and promote evidence-based approaches to pain management. While opioid pain medications may be effective in alleviating both acute and chronic pain in some patients, they are also associated with dangerous side effects including dependence and addiction. This program maintains access to these medications while prioritizing patient safety and controlling costs.

The WellManaged – Opioids program, launched in 2014 to address the opioid crisis, leverages Morphine Equivalent Dose (MED) checks at the point-of-sale (prior to pharmacy dispensing) to ensure high dosage patients are being carefully monitored by their providers and receiving appropriate prescriptions. These MED checks take into account all of the pain medications a patient is prescribed and combine their dosing totals instead of looking only at the dosage levels of each drug individually. Using advanced pharmacy technology, patients who are prescribed potentially inappropriate concomitant medications with opioids, such as benzodiazepines or muscle relaxers, are identified and actionable reports are created for both prescriber and patient outreach.

WellManaged – Respiratory helps clients control costs, ensure appropriate utilization, and improve the overall quality of care for asthma and chronic obstructive pulmonary disease (COPD) patients. Uncontrolled asthma can lead to increased emergency room visits, hospitalizations and fatalities, and COPD is the third leading cause of death in the United States. Due to the prevalence of these diseases in our society and their associated treatment costs, asthma and COPD medications are typically one of the top ten therapeutic cost drivers for our clients. Therefore, the WellManaged – Respiratory program includes an aggressively managed formulary, adherence interventions, and patient education to ensure optimal clinical outcomes while containing costs.